Standout Papers

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis 2022 2026 2023 2024129
  1. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis (2022)
    Bern-Thomas Nyang’wa, Catherine Berry et al. New England Journal of Medicine

Immediate Impact

2 from Science/Nature 52 standout
Sub-graph 1 of 22

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
Multidrug-resistant tuberculosis
2024 Standout
8 intermediate papers

Works of Mohammed Rassool being referenced

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis
2022 Standout
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
2019
and 2 more

Author Peers

Author Last Decade Papers Cites
Mohammed Rassool 537 309 140 24 717
Cloete van Vuuren 467 261 250 28 789
Joseph Kwong‐Leung Yu 461 227 160 25 661
Douglas Shaffer 254 181 64 30 752
Megan O’Brien 431 206 141 33 773
Cándida Medina 445 281 237 43 675
Anushka Naidoo 538 402 83 32 754
Montserrat Tuset 460 201 165 48 760
Vivian Cox 607 389 129 41 705
Anna Turkova 443 290 88 47 610
Esther C. Casas 512 416 105 29 638

All Works

Loading papers...

Rankless by CCL
2026